MTOR and esophageal squamous cell carcinoma: Telmisartan treatment reduced tumor volumes in ESCC/EAC xenograft mouse models by regulating the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) transduction pathway and inducing cell cycle arrest [144,145].